Gabriel Sanfélix-Gimeno

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1004386/publications.pdf

Version: 2024-02-01

76 papers 1,611 citations

304368 22 h-index 37 g-index

93 all docs 93
docs citations

93 times ranked 2413 citing authors

#	Article	IF	CITATIONS
1	Group-based Trajectory Models. Medical Care, 2013, 51, 789-796.	1.1	188
2	Prevalence of attention deficit hyperactivity disorder among children and adolescents in Spain: a systematic review and meta-analysis of epidemiological studies. BMC Psychiatry, 2012, 12, 168.	1.1	115
3	Use of Osteoporosis Medications after Hospitalization for Hip Fracture: A Cross-national Study. American Journal of Medicine, 2015, 128, 519-526.e1.	0.6	98
4	Antibiotic Use in Children – A Cross-National Analysis of 6 Countries. Journal of Pediatrics, 2017, 182, 239-244.e1.	0.9	90
5	The population-based prevalence of osteoporotic vertebral fracture and densitometric osteoporosis in postmenopausal women over 50 in Valencia, Spain (the FRAVO Study). Bone, 2010, 47, 610-616.	1.4	61
6	Timing of surgery for hip fracture and in-hospital mortality: a retrospective population-based cohort study in the Spanish National Health System. BMC Health Services Research, 2012, 12, 15.	0.9	53
7	Adherence to Evidence-Based Therapies After Acute Coronary Syndrome: A Retrospective Population-Based Cohort Study Linking Hospital, Outpatient, and Pharmacy Health Information Systems in Valencia, Spain. Journal of Managed Care Pharmacy, 2013, 19, 247-257.	2.2	46
8	Prevalence of osteoporotic fracture risk factors and antiosteoporotic treatments in the Valencia region, Spain. The baseline characteristics of the ESOSVAL cohort. Osteoporosis International, 2013, 24, 1045-1055.	1.3	44
9	Control of arterial hypertension in Spain. Journal of Hypertension, 2012, 30, 168-176.	0.3	43
10	Impact of osteoporosis and vertebral fractures on quality-of-life. a population-based study in Valencia, Spain (The FRAVO Study). Health and Quality of Life Outcomes, 2011, 9, 20.	1.0	41
11	Epidemiology of schizophrenia and its management over 8-years period using real-world data in Spain. BMC Psychiatry, 2020, 20, 149.	1.1	37
12	Medication Adherence Patterns after Hospitalization for Coronary Heart Disease. A Population-Based Study Using Electronic Records and Group-Based Trajectory Models. PLoS ONE, 2016, 11, e0161381.	1.1	35
13	Effect of cost sharing on adherence to evidence-based medications in patients with acute coronary syndrome. Heart, 2017, 103, 1082-1088.	1.2	34
14	Data Resource Profile: The Valencia Health System Integrated Database (VID). International Journal of Epidemiology, 2020, 49, 740-741e.	0.9	34
15	Oral Anticoagulants Initiation in Patients with Atrial Fibrillation: Real-World Data from a Population-Based Cohort. Frontiers in Pharmacology, 2017, 8, 63.	1.6	30
16	Primary Nonadherence to Oral Anticoagulants in Patients with Atrial Fibrillation: Real-World Data from a Population-Based Cohort. Journal of Managed Care & Specialty Pharmacy, 2018, 24, 440-448.	0.5	30
17	Primary and secondary non-adherence to osteoporotic medications after hip fracture in Spain. The PREV2FO population-based retrospective cohort study. Scientific Reports, 2017, 7, 11784.	1.6	27
18	Vertebral fracture risk factors in postmenopausal women over 50 in Valencia, Spain. A population-based cross-sectional study. Bone, 2013, 52, 393-399.	1.4	26

#	Article	IF	Citations
19	Coauthorship and Institutional Collaborations on Cost-Effectiveness Analyses: A Systematic Network Analysis. PLoS ONE, 2012, 7, e38012.	1.1	25
20	When Are Statins Cost-Effective in Cardiovascular Prevention? A Systematic Review of Sponsorship Bias and Conclusions in Economic Evaluations of Statins. PLoS ONE, 2013, 8, e69462.	1,1	25
21	Estimating Adherence Based on Prescription or Dispensation Information: Impact on Thresholds and Outcomes. A Real-World Study With Atrial Fibrillation Patients Treated With Oral Anticoagulants in Spain. Frontiers in Pharmacology, 2018, 9, 1353.	1.6	24
22	The effect of telehealth, telephone support or usual care on quality of life, mortality and healthcare utilization in elderly high-risk patients with multiple chronic conditions. A prospective study. Medicina ClÃnica, 2018, 151, 308-314.	0.3	23
23	Increasing Trends in Opioid Use From 2010 to 2018 in the Region of Valencia, Spain: A Real-World, Population-Based Study. Frontiers in Pharmacology, 2020, 11, 612556.	1.6	23
24	Effectiveness of Safety Warnings in Atypical Antipsychotic Drugs. Drug Safety, 2009, 32, 1075-1087.	1.4	22
25	Quality of INR control and switching to non-Vitamin K oral anticoagulants between women and men with atrial fibrillation treated with Vitamin K Antagonists in Spain. A population-based, real-world study. PLoS ONE, 2019, 14, e0211681.	1.1	22
26	Development and validation of a population-based prediction scale for osteoporotic fracture in the region of Valencia, Spain: the ESOSVAL-R study. BMC Public Health, 2010, 10, 153.	1.2	18
27	Adherence to oral anticoagulants in patients with atrial fibrillation—a population-based retrospective cohort study linking health information systems in the Valencia region, Spain: a study protocol. BMJ Open, 2015, 5, e007613.	0.8	15
28	Trends and area variations in Potentially Preventable Admissions for COPD in Spain (2002–2013): a significant decline and convergence between areas. BMC Health Services Research, 2016, 16, 367.	0.9	15
29	Agreement between semi-automatic radiographic morphometry and Genant semi-quantitative method in the assessment of vertebral fractures. Osteoporosis International, 2012, 23, 2129-2134.	1.3	14
30	Impact on the Population of Different Bone Mineral Density Testing Criteria and Appropriateness of Densitometries in the ESOSVAL Cohort, Spain. Journal of Clinical Endocrinology and Metabolism, 2014, 99, 142-150.	1.8	13
31	Burden of disease assessment with summary measures of population health for the Region of Valencia, Spain: a population-based study. Medicina ClÃnica, 2013, 140, 343-350.	0.3	12
32	Antipsychotic utilization patterns among patients with schizophrenic disorder: a cross-national analysis in four countries. European Journal of Clinical Pharmacology, 2019, 75, 1005-1015.	0.8	12
33	Overuse and Underuse of Antiosteoporotic Treatments According to Highly Influential Osteoporosis Guidelines: A Population-Based Cross-Sectional Study in Spain. PLoS ONE, 2015, 10, e0135475.	1.1	12
34	Coste-efectividad del tratamiento farmacológico del trastorno por déficit de atención e hiperactividad en niños y adolescentes: sÃntesis cualitativa de la evidencia cientÃfica. Revista De PsiquiatrÃa Y Salud Mental, 2013, 6, 168-177.	1.0	11
35	Improving the accuracy of medication adherence measures using linked prescription and dispensation data: findings from the ESOSVAL cohort of patients treated with osteoporosis drugs. Current Medical Research and Opinion, 2019, 35, 1535-1544.	0.9	11
36	A population-based screening for hepatitis C antibodies and active infection using a point-of-care test in a low prevalence area. PLoS ONE, 2020, 15, e0228351.	1,1	11

#	Article	IF	Citations
37	Prevalence, determinants, and inappropriateness of calcium supplementation among men and women in a Spanish Mediterranean area: Cross-sectional data from the ESOSVAL cohort. Journal of Bone and Mineral Research, 2013, 28, 2286-2294.	3.1	10
38	Trends of uncontrolled blood pressure in Spain. Journal of Hypertension, 2013, 31, 630-631.	0.3	10
39	Real-world adherence to oral anticoagulants in atrial fibrillation patients: a study protocol for a systematic review and meta-analysis. BMJ Open, 2018, 8, e025102.	0.8	10
40	Did HEDIS Get it Right? Evaluating the Quality of a Quality Measure. Medical Care, 2014, 52, 669-676.	1.1	9
41	Clinical outcomes of nonvitamin K oral anticoagulants and acenocoumarol for stroke prevention in contemporary practice: A populationâ€based propensityâ€weighted cohort study. British Journal of Clinical Pharmacology, 2021, 87, 632-643.	1.1	9
42	Trends and Geographical Variability in Osteoporosis Treatment After Hip Fracture: A Multilevel Analysis of 30,965 Patients in the Region of Valencia, Spain. Journal of Bone and Mineral Research, 2020, 35, 1660-1667.	3.1	7
43	Incidence of Subsequent Hip Fracture and Mortality in Elderly Patients: A Multistate Population-Based Cohort Study in Eastern Spain. Journal of Bone and Mineral Research, 2020, 37, 1200-1208.	3.1	7
44	Impact of a multifaceted intervention to improve the clinical management of osteoporosis. The ESOSVAL-F study. BMC Health Services Research, 2010, 10, 292.	0.9	5
45	Are prescribing doctors sensitive to the price that their patients have to pay in the Spanish National Health System?. BMC Health Services Research, 2011, 11, 333.	0.9	5
46	Can purchasing information be used to predict adherence to cardiovascular medications? An analysis of linked retail pharmacy and insurance claims data. BMJ Open, 2016, 6, e011015.	0.8	5
47	Impact of Drug Safety Warnings and Cost-Sharing Policies on Osteoporosis Drug Utilization in Spain: A Major Reduction But With the Persistence of Over and Underuse. Data From the ESOSVAL Cohort From 2009 to 2015. Frontiers in Pharmacology, 2019, 10, 768.	1.6	5
48	Efficacy of osteoporosis therapies in a network meta-analysis with indirect comparisons: many concerns for new tools of evidence synthesis?. Osteoporosis International, 2013, 24, 1927-1928.	1.3	4
49	Cost-effectiveness of pharmacological treatment of attention deficit hyperactivity disorder in children and adolescents: Qualitative synthesis of scientific evidence. Revista De PsiquiatrÃa Y Salud Mental (English Edition), 2013, 6, 168-177.	0.2	4
50	A Multilevel Analysis of Real-World Variations in Oral Anticoagulation Initiation for Atrial Fibrillation in Valencia, a European Region. Frontiers in Pharmacology, 2017, 8, 576.	1.6	4
51	Treatment patterns and appropriateness of antipsychotic prescriptions in patients with schizophrenia. Scientific Reports, 2021, 11, 13509.	1.6	4
52	Prevalence of densitometric osteoporosis and osteopenia in Spain. Bone, 2011, 48, 668-669.	1.4	3
53	Trends in gastrointestinal bleeding in the Region of Valencia (2000-2005). Relationship to sales of nonsteroidal anti-inflammatory drugs and acid suppression medication. Farmacia Hospitalaria, 2011, 35, 289-297.	0.6	3
54	Adherence to and appropriateness of anti-osteoporotic treatments in patients aged 50 and over in the Valencia Region (Spain). The ESOSVAL-AD Study. BMC Musculoskeletal Disorders, 2011, 12, 178.	0.8	3

#	Article	IF	CITATIONS
55	Rationale and design of a pragmatic clinical trial to assess the impact of self-monitoring blood pressure at home and self-titration of antihypertensive medication in poorly controlled hypertension: the ADAMPA study protocol. BMC Family Practice, 2018, 19, 160.	2.9	3
56	La prescripción farmacéutica en Atención Primaria. Mucho más que un problema de gasto. , 2011, , 53-70.		3
57	Primary care doctors' views on self-monitoring of blood pressure and self-titration among patients with uncontrolled hypertension in Spain. The ADAMPA trial focus group study BJGP Open, 2020, 4, bjgpopen20X101062.	0.9	3
58	Real-World Management and Clinical Outcomes of Stroke Survivors With Atrial Fibrillation: A Population-Based Cohort in Spain. Frontiers in Pharmacology, 2021, 12, 789783.	1.6	3
59	Carpal tunnel release surgery: small-area variation and impact of ambulatory surgery in the autonomous region of Valencia, Spain. Gaceta Sanitaria, 2013, 27, 214-219.	0.6	2
60	Effectiveness and Safety of New and Traditional Oral Anticoagulants in a Population-Based Cohort of New Users with Atrial Fibrillation. Value in Health, 2015, 18, A378.	0.1	2
61	Effect of Drug Cost-Sharing Change on Non-Adherence to Essential Medications for Acute Coronary Syndrome: A Population Based Natural Experiment. Value in Health, 2016, 19, A659.	0.1	2
62	Real-World Patterns of Pharmacotherapeutic Management of Asthma Patients With Exacerbations in the Spanish National Health System. Frontiers in Pharmacology, 2020, 11, 1323.	1.6	2
63	Association of Vitamin K and Nonâ€Vitamin K Oral Anticoagulant Use and Cancer Incidence in Atrial Fibrillation Patients. Clinical Pharmacology and Therapeutics, 2022, 111, 200-208.	2.3	2
64	Predictive Performance of the FRAX Tool Calibrated for Spain vs. an Age and Sex Model: Prospective Cohort Study with 9082 Women and Men Followed for up to 8 Years. Journal of Clinical Medicine, 2022, 11, 2409.	1.0	2
65	Prevalence of osteoporosis in the ESOSVAL cohort: reply to the comment by Pedrera-Zamorano et al Osteoporosis International, 2013, 24, 1925-1926.	1.3	1
66	Primary Non-Adherence to Antiosteoporotic Treatment and Associated Factors: A Prospective Cohort Study in Spain. Value in Health, 2015, 18, A650.	0.1	1
67	Variations in osteoporosis medication utilization. A population-based ecological cross-sectional study in the region of Valencia, Spain. PLoS ONE, 2018, 13, e0199086.	1.1	1
68	Group-based Trajectory Models to Assess Quality of INR Control and Its Association With Clinical Outcomes. Medical Care, 2020, 58, e23-e30.	1.1	1
69	Impact of Three Safety Interventions Targeting Off-Label Use of Immediate-Release Fentanyl on Prescription Trends: Interrupted Time Series Analysis. Frontiers in Pharmacology, 2022, 13, 815719.	1.6	1
70	PHP7 Orphan Drugs for Rare Diseases in the European Union: Bridging the Gap between Drug Development and Unmet Medical Needs?. Value in Health, 2011, 14, A334.	0.1	0
71	PCV28 Control of Hypertension in Spain: A Systematic Review and Meta-Analysis of 76 Epidemiological Studies on 341,632 Participants. Value in Health, 2011, 14, A369.	0.1	0
72	PCV71 Sponsorship and Pharmacoeconomic Conclusions of Studies on Statin Use for Cardiovascular Prevention: A Systematic Analysis. Value in Health, 2011, 14, A377.	0.1	0

#	Article	IF	CITATIONS
73	P1-316 Population impact and appropriateness of treatment according to different osteoporosis guidelines. Journal of Epidemiology and Community Health, 2011, 65, A155-A155.	2.0	0
74	Primary Non-Adherence, Early Non-Persistence, Treatment Reinitiation and Long-Term Adherence Among A Population-Based Cohort of NaÃ-ve Patients Prescribed Antiosteoporotics. Value in Health, 2016, 19, A532.	0.1	0
75	Variation in Antiosteoporotic Drug Prescribing and Spending Across Spain. A Population-Based Ecological Cross-Sectional Study. Frontiers in Pharmacology, 2018, 9, 342.	1.6	O
76	Costâ€Sharing Increase, Medication Adherence, and Hospitalizations in Schizophrenia Patients: A Natural Experiment. Clinical Pharmacology and Therapeutics, 2021, 110, 1490-1497.	2.3	0